Journal article
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers
DL Aisner, TT Nguyen, DD Paskulin, AT Le, J Haney, N Schulte, F Chionh, J Hardingham, J Mariadason, N Tebbutt, RC Doebele, AJ Weickhardt, M Varella-Garcia
Molecular Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2014
Abstract
Activated anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases, through gene fusions, have been found in lung adenocarcinomas and are highly sensitive to selective kinase inhibitors. This study aimed at identifying the presence of these rearrangements in human colorectal adenocarcinoma specimens using a 4-target, 4-color breakapart FISH assay to simultaneously determine the genomic status of ALK and ROS1. Among the clinical colorectal cancer specimens analyzed, rearrangement-positive cases for both ALK and ROS1 were observed. The fusion partner for ALK was identified as EML4 and the fusion partner for one of the ROS1-positive cases was SLC34A2, the partner for the other ROS1-positive c..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
This study was partially supported by research grants from Abbott Molecular (to M. Varella-Garcia), Boettcher Foundation (to R.C. Doebele), and the NCI CCSG P30CA046934 (Molecular Pathology Shared Resource). T.T. Nguyen was supported by the Cancer Research Summer program from the University of Colorado Cancer Center. D.D. Paskulin was a fellow from the Brazilian Agency CAPES. A.J. Weickhardt was supported by an NHRMC postgraduate Fellowship and Roche HOTT Fellowship.